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Abstract  
Resuscitation fluid therapy -a systematic review of principles and cross-sectional study of clinical practice 
Master thesis in Medicine; Daniel Olsson, Sophie Lindgren - Institute of Clinical Sciences 
Programme in Medicine Gothenburg, Sweden 2015 
Background: Saline solution has been used in fluid resuscitation since the 19th century. Different colloids 
have been used the last 60 years. Choice of resuscitation fluid has varied over the years and has been 
heavily influenced by local traditions and clinicians preference. 
Method: This article consists of a systematic review and meta-analysis of current resuscitation fluid 
research combined with a survey at the Department of Anesthesia and Intensive Care at Sahlgrenska 
University Hospital backed with data of resuscitation fluid usage at Sahlgrenska University Hospital.  
Results: In patients with sepsis albumin has been shown to decrease mortality compared to saline 
solution and HES increases risk of renal replacement therapy and may increase mortality. In a 
perioperative setting such risks with HES has not been identified. In both ICU and perioperative 
environment balanced crystalloid seem superior to saline solution.  
Out of 62 respondents in our survey 56% and 69% answered that they used both crystalloids and colloids 
for perioperative and sepsis resuscitation respectively, and 74% that their first perioperative choice was 
HES. However, when treating septic shock, 89% answered that their preferred colloid was albumin. 
Conclusion: Balanced crystalloids have an important role in fluid resuscitation. Albumin is the preferred 
colloid in severe sepsis but in other scenarios HES may be considered.  
The anesthesiologists at the Department of Anesthesia and Intensive Care had a good adherence to 
current research although perioperative albumin use ought to be reconsidered due to high cost and lack 
of evidence.   
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Introduction 
Background 
Historical background 
Intravenous fluid resuscitation with saline solutions is believed to originate from 1830s England during 
the time of the Indian Blue Cholera pandemic that struck the country in 1831. The same year 
O’Shaughnessy was the first to propose “injection of highly oxygenated salts into the venous system” in 
his paper publicized in Lancet (at age 22!). The theory of oxygenation was soon abandoned to instead 
focus on water and electrolyte replacement. Early 1832 the first treatments of human subjects were 
conducted by O’Shaughnessy and later Latta. Of Lattas first four patients only one survived but Latta 
continued unwavering and modified his solution through several experiments finally arriving at a fairly 
physiological solution containing 134 mmol/L Sodium, 118 mmol/L Chloride and 16 mmol/L Bicarbonate 
(See table 1 for human plasma reference). In 1833 came a decline in the development of fluid 
resuscitation as cholera in England subsided and the two main proponents of saline infusion disappeared 
from the field (Latta died from pulmonary tuberculosis and O’Shaughnessy, not unlike the youth of 
today, left for India to study the medical use of cannabis) [1, 2].  
Advancement in hemorrhage treatment breathed new life into the field of fluid resuscitation. Several 
researchers put their names on different solutions. Among these where Sydney Ringer who presented 
his Ringer’s solution in 1883 based on his experiments on frogs where he determined that 0.75% saline 
“…makes an excellent circulating fluid…”.  Nasse would later define physiological saline in frogs to be 
0.6%. The conclusions drawn from frogs were challenged by HJ Hamburger who in 1896 claimed 0.92% 
to be the saline concentration of mammalian blood based on his research on cell lysis and the freezing 
point of blood. 0.9% normal saline, even though not as normal as Hamburger claimed (See table 1), 
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became the world’s most common resuscitation fluid and still is. The simplicity of adding salt to water is 
a possible explanation [1]. 
Colloid solutions used for fluid resuscitation is a product of the 20th century. Albumin became available 
after the invention of blood fractionation and was used as an infusion during world war II in the US [3]. 
Contemporary to this, Grönwall and Ingelmans research on dextran led to the development of Macrodex 
[4]. Hydroxyethyl starch is the youngest colloid in the family. In 1959 waxy hydroxyethyl starch polymers 
first became available and was tested on man by Ballinger et al in 1966 [5].   
 
Physiological background  
In medicine, shock is generally defined as circulatory failure resulting in inadequate cellular oxygenation 
and waste removal.  Shock can also be defined as a cause of inadequate cardiac output (CO). Usually CO 
is decreased during shock but extreme metabolic rate and abnormal tissue perfusion can cause 
circulatory shock although cardiac output remains normal [6].  
A common way to categorize circulatory shock is to divide it into four subtypes based on their 
pathophysiology; 1) distributive, where vasodilation diminish venous return, 2) hypovolemic, i.e. lack of 
circulating volume which also diminishes venous return, 3) cardiogenic, diminished pumping ability from 
e.g. myocardial infarction and finally 4) obstructive, where pumping function is externally hindered e.g. 
from a cardiac tamponade [6, 7]. 
Septic shock 
Septic shock is the most frequent cause of circulatory shock in ICU patients and also the most common 
cause of shock-related death in modern hospitals. As such, it deserves special mentioning. Septic shock is 
caused by an exacerbated bacterial infection that spreads to several tissues through the blood. With a 
multitude of possible bacterial agents causing septic shock, it displays in many different ways. Typical 
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though is substantial vasodilation, especially in the infected tissue. About half of the septic shock 
patients suffer from circulatory shock despite a high cardiac output due to high temperature and high 
cellular metabolism stimulated by bacterial toxins. Increased amount of carbonic and lactic acid in the 
tissues makes the blood more acidic and thus prone to local agglutination, a phenomenon called 
sludging. Micro blood clots may also form as a result. If widespread, this leads to disseminated 
intravascular coagulation (DIC) where coagulation factors are consumed, causing lethal hemorrhaging. 
End stage septic shock is very similar to hemorrhagic shock [6, 7].  
Hemorrhagic shock 
Hemorrhagic shock is more or less synonymous with hypovolemic shock as hemorrhage is the most 
common cause of hypovolemic shock. Bleeding diminishes filling pressure and reduces venous return 
which in turn reduces cardiac output (CO). It is possible to lose 10 percent of the total intravascular 
volume before CO is affected. Decrease of arterial pressure (ABP) usually occurs later than CO and 
typically not until 20% volume loss. At about 45% blood loss ABP reaches zero, though a person seldom 
survives more than 30-40% blood loss (without resuscitation). Vasoconstriction due to sympathetic 
reflexes is the reason why ABP decrease lags behind CO reduction [6]. 
From level of severity, hemorrhagic shock is divided into two subcategories; Non-progressive and 
Progressive. Shock is considered non-progressive when the subject is able to compensate and recover 
without external intervention. If the hemorrhage reaches a critical level though, the shock becomes 
progressive. When progressive, the shock starts to feed itself through several positive feedback loops. 
With low enough ABP, cardiac blood flow decreases leading to cardiac depression further hampering CO. 
By the same principle the vasomotor center becomes suppressed. As in septic shock sludging occurs. 
Capillary hypoxia also triggers increased permeability, further decreasing circulating volume. Acidosis 
due lactic acid and carbon dioxide production ads to this vicious circle that will cause the death of the 
individual if not reversed [6].  
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Distribution of Fluid 
In human adults body fluid constitutes about 50% of the total weight in women and about 60% in men. 
This fluid is distributed 2/3 intracellular and 1/3 extracellular. The extracellular fluid, 11.7-14L in a 70kg 
human, consists of 3/4 interstitial fluid and 1/4 Plasma (3-3.5L). Assuming a hematocrit of 0.4, average 
blood volume is 5-5.8L [6].  
Based on the theories of Starling, fluid distribution between interstitium and plasma is governed by 
hydrostatic and colloid osmotic force while distribution over the cellular membrane depends 
predominantly on the osmotic effect of sodium, chloride and other smaller solutes.  Most resuscitation 
fluids today strive to be isotonic, similar to extracellular fluid in electrolyte content, aimed at not 
disturbing the fluid balance between the intra- and extracellular compartments [6, 8]. Colloid osmotic 
pressure is derived from molecules less able to pass through the semipermeable membranes of vessels, 
thus exerting osmotic pressure. Different colloid solutions are widely used in fluid resuscitation with the 
presumption that increased colloid osmotic pressure in the plasma will retain the fluid there while 
crystalloids (resuscitation fluids lacking colloids) will distribute over the whole extracellular volume. By 
this concept, a simplified model is that 1000 ml of intravenous crystalloid will add 250 ml to the 
circulating plasma while 1000 ml of intravenous colloid will add 1000 ml to the circulating [6]. Some 
guidelines use a 1:3 colloid to crystalloid ratio, roughly based on the same principle [8]. 
Recent technological leaps in visualization have allowed closer study of the endothelial glycocalyx and its 
role in fluid exchange and a need to revise our views based on Starling. The endothelial glycocalyx 
consists of glycoproteins and proteoglycans coating the lumen of blood vessels and varies in thickness 
from 0.2 to 8 µm (average 2 µm) depending on vessel size. Measurements suggests that its volume might 
be as high as 1700 ml in the average human, thus, rather than seeing vascular content as plasma and 
erythrocytes one ought to consider viewing it as plasma, erythrocytes and glycocalyx [9].  
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The endothelial glycocalyx is semipermeable, stopping larger molecules such as dextran 70 or 
hydroxyethyl starch. It is suggested that the colloid osmotic pressure gradient is active between plasma 
and the subglycocalyx spatium rather than between plasma and the interstitium. Inflammatory states 
(such as sepsis, trauma or surgery) damage the endothelial glycocalyx, underlining the importance of its 
further study. Even the chronic inflammation of diabetes has shown to damage the glycocalyx, adding 
the question if this patient group needs special attention in fluid resuscitation. Although endothelial 
glycocalyx is an exciting new area of research in itself, this article will focus on the resuscitation fluids we 
are using in today’s medicine [9].  
 
Fluid therapy in practical medicine 
In the field of Intensive and perioperative medicine, intravenous infusion of fluid is without question one 
of the most common interventions.  
To make a simplified distinction of use, fluid is given as maintenance or fluid resuscitation. The main bulk 
of fluid therapy is of course given as fluid balance maintenance and will not be covered in this study. 
Fluid resuscitation on the other hand refers to treatment of an acute ailment, mainly hypovolemia. In the 
intensive care unit (ICU) common reasons for fluid resuscitation are trauma and severe sepsis/septic 
shock. Perioperatively, blood loss is the main reason. A distinct difference between these settings is that 
ICU patients are obviously severely ill with possible multi organ engagement whereas a majority of 
elective surgery patients presents a limited problem in need of surgical treatment.   
Regardless of type of patient and setting, fluid therapy is a treatment involving a large number of 
different pharmacological products and there is a vast amount of known complications to fluid 
distribution such as allergic reactions, fluid overload with formation of tissue edema, electrolyte 
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disturbances and kidney failure. Type of fluid loss and the individual patient’s condition is of importance 
and should also be taken into consideration when choosing and prescribing intravenous fluid treatment. 
 
Choice of resuscitation fluid 
A typical way to classify resuscitation fluids is by dividing them into crystalloids and colloids. Choice 
between and within these two groups is generally based on their physiological qualities but also lean 
heavily on local tradition and the clinicians own preferences. Below, table 1 shows the composition of 
some of the more common resuscitation fluids. 
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Table 1 [8, 10] Composition of solutes in human plasma and a selection of resuscitation fluids 
*Baxalta Inc. has been contacted but cannot confirm a figure for the Osmolarity of Flexbumin. 
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Crystalloids 
Internationally, the most commonly used crystalloid is normal saline 0.9% [1]. There are also different 
balanced solutions where the most common are Ringer’s lactate, Ringer’s acetate and Plasmalyte. By 
tradition Ringer’s acetate is the most common crystalloid in Nordic countries but seems to see little use 
elsewhere. 
Colloids 
Most colloids consist of a saline solution with added macromolecules but some are based on more 
balanced solutions. There are a number of colloid groups;  
Albumin is derived from human donors and heated to prevent spreading of disease. Compared to 
semisynthetic colloids, it’s considerably more expensive. Albumin has a molecular weight averaging 
69 000 Da [6, 8]. 
Hydroxyethyl starch (HES) is derived from either maize or potato starch. HES comes in many different 
sizes, but modern HES solution molecules weigh 130 000 Da and the ratio of hydroxyethyl groups on the 
starch molecule is in the range of 0.38-0.42. HES is the most commonly used semisynthetic colloid in 
Europe [8, 10]. 
Dextran is a polysaccharide produced by Leuconostoc mesenteroides bacteria in sucrose solution. 
Molecular weights normally used are 40 000 and 70 000 Da (Rheomacrodex and Macrodex respectively). 
Anaphylactic reactions are comparatively common and prophylactic Promiten must be given before 
infusion. Internationally, dextran sees little use in fluid resuscitation [4, 8, 10]. More commonly dextrans 
are used as perioperative thrombosis prophylaxis [11].  
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Gelatin solutions are commonly based on bovine gelatin. Molecular weight vary around 30-35 000 Da 
[10].  
  
Past and present controversies 
Throughout history physicians has debated what treatments to use and the field of fluid resuscitation is 
not spared. At the turn of the century the debate of crystalloids vs colloids for fluid resuscitation was 
rekindled when new meta-analyses surfaced. Foremost albumin became a subject of controversy [12]. 
The Cochrane injuries group changed the view on albumin in intensive care more or less over night with 
a report showing a pooled relative risk of death using albumin vs other fluids of 1.68 (95% CI 1.26-2.23) 
[13]. At Sahlgrenska University Hospital, spending on albumin dropped by 64% the following year, 1999 
[12]. 10 years later, hydroxyethyl starches (HES) came to be questioned as a widely renowned researcher 
and proponent of HES, professor Joachim Boldt was revealed as a fraud [14, 15]. Several of his articles 
were withdrawn and the scientific community was left with a knowledge vacuum [14]. With one of the 
biggest proponents of HES gone and the publication of several large randomized trials on the subject [16-
18], the pendulum swung for HES in intensive medicine. In 2013 The U.S Food and Drug Administration 
(FDA) released an official recommendation against using HES when treating critically ill patients with 
renal dysfunction and patients undergoing open heart surgery. The recommendations also stated that 
patients should be informed of the risks involved, and that renal function should be monitored at least 
90 days [19]. It was also stated that HES infusion should be discontinued at any sign of coagulopathy. The 
European Medicines Agency’s (EMA) branch Pharmacovigilance Risk Assessment Committee (PRAC) 
adopted similar restrictions, also in 2013 [20]. The EMA-PRAC statement varied from that of FDA in that 
EMA-PRAC excludes HES for treating burn victims and do not exclude use in open cardiac surgery. 
Notably the EMA-PRAC statement gives no references to why burn victims are excluded. If this is the last 
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word in the colloids debate remains to be seen though. During the last two decades several studies has 
assessed several different aspects and impacts of fluid resuscitation which will be given an in depth 
analysis in this article.  
 
Aim 
This study aims to systematically review recent international research concerning choice of resuscitation 
fluid in ICU and perioperative patients and compare this to local praxis in a large university clinic.  
 
Research question 
Which type of fluid is recommended internationally in ICU treatment and in perioperative care and how 
is the Sahlgrenska Anaesthesia and Intensive care clinic’s concordance to this? Are crystalloids or colloids 
preferred, and what type within these groups? 
 
Materials and Methods 
Setting  
Sahlgrenskas Department of Anesthesia and Intensive Care is the largest unit of its kind in Sweden [21]. 
This unit employs around 100 anesthesiologists who regularly have to consider fluid resuscitation regime 
in both an ICU environment and in the operating theatre. Sahlgrenska University Hospital employs about 
16 000 people serving some 1950 beds [22]. 
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Study design 
This study consists of four parts; a systematic review and a meta-analysis combined with a cross-
sectional survey and a retrospective view on resuscitation fluid consumption. To assure the quality of 
this review, the PRISMA checklist was used [23]. 
 
Data collection procedures 
Systematic review 
To capture the most recent research in the field only studies published 2001-2015 which investigated 
effectiveness of resuscitation fluids in ICU and perioperative care were considered for inclusion. Articles 
not written in English or not available in full text through Gothenburg University were excluded. Search 
for unpublished data was not made. Since cardiac surgery patients usually receive treatment at a 
separate ICU/operating clinic, articles focusing on cardiac surgery patients were excluded. MeSH terms 
used where; Double-blind, Fluid Therapy, Fluid Resuscitation, Crystalloid (Solutions), Colloid (Solutions), 
Isotonic Solutions, Albumin, Hydroxyethyl Starch, Plasmalyte, Ringer’s acetate, Ringer’s lactate, Sepsis, 
Critical Illness, Renal Replacement Therapy, Intensive Care Unit and Perioperative (Period). To identify 
eligible studies, the MEDLINE database and Google Scholar was used. Two reviewers (the authors) 
independently screened titles and abstracts of the identified studies to filter out those not meeting 
criteria for inclusion.  Eligible studies were read through by the same two reviewers and evaluated using 
the Jadad scoring method [24]. Those deemed to have the highest scientific value were chosen for 
inclusion in this article. 
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Meta-analysis 
When performing the meta-analysis, only studies comparing crystalloid vs. colloid treatment were 
included (See Table 2 and 3 and Figure 1 and 2).  
 
Cross-sectional Survey 
An anonymous web based survey was sent out to all anaesthesiologists (n=100) employed at the 
Department of Anesthesia and Intensive Care at Sahlgrenska University Hospital (SU).  The survey 
consisted of 6 questions (appendix 1) and was sent out by e-mail linked to surveymonkey.com. 
 
Retrospective data on fluid consumption and expense 
Statistical information on fluid and blood product consumption and expense in the Department of 
Anaesthesiology and Intensive Care in SU as well as the whole hospital was collected from the physician 
responsible of pharmaceuticals in the anaesthesia department and from the Sahlgrenska Immunology & 
Transfusion medicine clinics research nurse. 
 
Data-analysis 
Systematic review 
The included studies are summarized in table 2 and 3. Similarities in end points where identified and the 
results were sorted and analysed according to which substances that were assessed in the studies. 
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Meta-analysis 
For dichotomous data, we calculated the odds ratios (OR) and risk ratios (RR) with 95% confidence 
intervals using the Mantel–Haenszel random effects model and weighted averages. The significant level 
of the overall effect was calculated regarding the OR of each outcome. Comprehensive Meta-analysis 
software version 3 (©2006-2015 Biostat Inc. Englewood, New Jersey, USA) was used for statistical 
analysis. 
 
Cross-sectional survey 
Results of the survey were compiled by Surveymonkey.com and the diagrams created from the data 
were made in Microsoft Excel®15.0 (©Microsoft corp. 2013). Since the survey was anonymous no 
individual responders could be identified. Thus no comparative statistical analysis was made. 
 
Retrospective data on fluid consumption and expense 
Data was compiled using Microsoft Excel®15.0 (©Microsoft corp. 2013) and spending on blood products 
were extrapolated using consumer price index and number of operations/patients treated. Statistics are 
only descriptive since it is not tied to any individuals.  
 
Ethics 
The responses to the questionnaire were reported anonymously. Other than that, no ethical 
considerations were made. Authorization from the ethics committee was deemed unnecessary.  
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Results 
Review of literature 
A total of 332 articles were found in the initial database search. After screening, 281 articles were 
excluded. 51 articles were assessed in their entirety and finally 20 articles were included in this study (Fig 
1). 13 of these were included in the meta-analysis. See Figure 1 below.  
 
Figure 1 Flow chart of study inclusion process.  
The 20 included articles were published between 2004 and 2015 and 15 of them were double blinded 
studies. The studies included 32015 patients (one article was a long term follow up and one was a 
subgroup analysis, these patients were not counted twice) and most of these were ICU patients. Table 2 
below gives an overview of the included articles.  
7 articles excluded based on 
end points
13 articles included in meta-
analysis
332 articles found in database 
searching
281 articles excluded after 
screening title and/or abstract
53 full-text articles assessed for 
eligibility
33 articles excluded based on 
full article
20 articles included in review
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Table 2 Characteristics of articles included in this study [16-18, 25-41] 
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Albumin 
Four [25, 27, 29, 35] articles included in this study investigates albumin vs control. Three of the studies 
are made in ICUs in industrialized countries. Maitland et al conducted their research in 6 clinical centres 
in Africa that lacked ICU capability [29]. No articles describing albumin use in a perioperative 
environment were found. 
One of the articles is a subgroup analysis of the same population [27]. None the less, a total of 5411 
Patients received albumin in these studies vs a total control population of 6460. Finfer et al.’s study from 
2004 (SAFE) carries most of the weight at 6933 of 11871 patients. 
The study by Maitland et al. was the only using mortality at 48h as an endpoint, which was very similar 
when comparing albumin to saline (Relative risk, RR=1.0, p=0.96). The main finding in this study was 
comparison of any bolus (albumin or saline) vs no bolus. Which showed an increased relative risk of 
death at 48h of 1.45 (95%CI 1.13-1.86 p=0.003) for the bolus groups [29]. None of the studies found a 
significant difference in mortality at 28 days in their original analysis. However, the predefined 
subgroups in the SAFE study found that brain injury patients who received albumin had an increased 
relative risk of mortality of 1.62 (95%CI 1.12-2.34 p=.009. Trauma patients in the same study showed a 
trend towards lower survival in the albumin group (p=0.06) whilst sepsis patients showed a trend 
towards better survival when receiving albumin (p=0.09). The later multivariate analysis of the sepsis 
subgroup in the SAFE study, adjusting for baseline differences, found that the albumin group had a 
favourable mortality odds ratio of 0.71 (95%CI 0.52-0.97 p=0.03). The study by Caironi et al. added an 
analysis of 90 day mortality but found no significant difference between albumin and control. A post hoc 
subgroup analysis by Caironi et al., singling out patients in septic shock, showed a lowered relative risk of 
mortality associated with albumin treatment of 0.87 (95%CI 0.77-0.99) [25, 27, 29, 35]. 
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The ratio of fluid administered to patients during the first four days in the SAFE study was approximately 
1:1.4 albumin-saline. There was no difference in total fluid administered in the study by Caironi et al. 
However, during the first seven days the albumin group had a significantly higher mean ABP and a lower 
cumulative fluid balance [25, 35]. 
  
Hydroxyethyl Starch 
Twelve articles [16-18, 28, 30, 33, 34, 36-38, 40, 41] in this review examined the effect of HES vs control. 
Five of these were performed in a perioperative environment. Of the seven studies performed in ICU 
environment, one is a long term follow up [38]. A total of 8430 patients were included in the ICU studies, 
Myburgh et al.’s study included 6742 of these, about 80% of the total ICU patients in HES vs control 
studies. 
None of the ICU studies found showed a significant difference in mortality at 28 days. At 90 days, only 
Perner et al. discovered an inconsistency with an increased relative risk in the HES group of 1.17 (95%CI 
1.01-1.36, p=0.03) [18]. Brunkhorst et al. found a non-significant trend towards higher mortality in the 
HES group (p=0.09) [16]. In the long term follow up by Perner et al., the difference in mortality was no 
longer significant at 6 or 12 months or at the time point of the longest follow up (13-36 months, median 
22 months). 
The presence of acute renal failure was also investigated by all the ICU studies. Brunkhorst et al. found 
that the HES group had a significantly higher rate of acute renal failure (34.9% vs 22.8%, p=0.002) in their 
study while Bechir et al. and Guidet et al. found no difference between the groups [16, 30, 33]. In the 
study by article by James et al. patients with penetrating trauma that received HES had significantly 
better renal outcome, i.e. lower number of patients in RIFLE (R=risk, I=injury, F=failure, L=loss, E=end 
stage) category R and I (p=0.043 and 0.018 respectively) [28]. A similar find was made by Myburgh et al. 
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where the saline group had a higher number of RIFLE R and I (p=0.007) [17]. In Perner et al.’s study on 
the other hand, a trend towards a higher number of RIFLE-I in the HES group was seen (p=0.08) [18].  
Three studies identified a significant difference in need of renal replacement therapy (RRT). In 
Brunkhorst et al.’s study, The HES group received RRT during 18.3% of the total stay in the ICU and the 
corresponding value in the  lactated Ringer’s group was 9.2% (p=0.001) [16]. Myburgh et al. showed an 
increased relative risk for RRT in the HES group of their study of 1.21 (95%CI 1.00-1.45 p=0.04), or 7% of 
the patients in the HES group vs 5.8% in the saline group [17]. Finally Perner et al. also found an increase 
in need of RRT in their HES group, 22% of the patients, vs 16% in the Ringer’s acetate group, relative risk 
1.35 (95%CI 1.01-1.80 p=0.04) [18]. 
When comparing total volume of fluid administered Bechir et al. and Perner et al. found no significant 
difference between HES and control [18, 33]. Guidet et al. did not find a difference in total fluid volume 
either but in their HES group, volume of fluid needed to achieve hemodynamic stabilization (HDS), was -
331ml (95%CI -640 - -21, p=0.0185) compared to control [30]. However, there was no significant 
difference in time to reach HDS between groups. Brunkhorst et al. found that HES normalized CVP faster 
(p=0.003) but there was no significant difference in MAP and ScvO2 changes between groups [16]. 
Myburgh et al. also registered a significantly faster CVP increase that remained higher day 0-2. Three 
studies found a difference in study fluid ratio, where Brunkhorst et al. and James et al. (penetrating 
trauma only) found that HES vs crystalloid was given at a 1:1.58 and 1:1.47 ratio the first 24h respectively 
[16, 28]. Study fluid ratio in the whole study of Brunkhorst et al. was 1:1.32 favouring HES [16]. During 
the first four days of Myburgh et al.’s study, the ratio was 1:1.17, favouring HES. Four studies found that 
HES patients received significantly more blood products [16-18, 28].  
In the five perioperative studies (491 patients) comparing HES and crystalloid, none found a significant 
difference in renal adverse effects [34, 36, 37, 40, 41]. Four studies reported creatinine values, of which 
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three studies also used NGAL (Neutrophil gelatinase-associated lipocalin) and urinary output 
measurements to define renal injury [34, 36, 37, 41]. Feldheiser et al. had the longest follow up, 5 
months after surgery, while the studies of Kancir et al. reported follow ups at 10-12 days and 15 days 
[34, 36, 41]. Yates et al. found no significant difference in overall postoperative complications, but when 
analysing presence of renal failure, the HES group had 4 cases (of 104 patients) while the crystalloid 
group (Hartmann’s solution) had none [40]. 
Regarding hemodynamic changes and its relation to total amount of fluid administered, Feldheiser et al. 
found that the trial fluid dose limit of the study protocol was reached faster (p=0.006) and more 
frequently (91.7% vs 62.5% p=0.036) and by using a larger total volume (p=0.0164) in the crystalloid 
group [34]. Yates et al. also found that less trial fluid volume was used in the HES group (p<0.001) at a 
ratio of 1:1.69 during the first 24h [40]. Despite this, Yates et al. found no difference in postoperative 
gastrointestinal morbidity [40]. Feldheiser et al. identified a higher stroke volume (95 vs 70 ml, p= 0.008) 
and CO (6.7 vs 4.7, p=0.002) in the HES group [34]. Likewise, Kancir et al’s study from 2014 found a 
higher postoperative MAP and diastolic blood pressure (DBP) (91vs83 and 72vs63 p<0.03) in the HES 
group. However, in their study from 2015 there was no significant difference in hemodynamic 
parameters between groups [36, 41]. Mercier et al. presented a lower risk of maternal hypotension 
during caesarean delivery when adding HES to the fluid preload treatment (odds ratio of 0.47 (95%CI 
0.25-0.87)) [37].  
 
Crystalloids 
Two studies comparing crystalloids where included in this review [26, 39]. Hadimioglu et al. investigated 
perioperative use of crystalloids. Their study revealed that patients receiving saline solution had both 
lower pH (p<0.05) and higher s-chloride (p<0.05) after surgery, compared to those receiving lactated 
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Ringer’s solution. In addition, patients receiving lactated Ringer’s solution had (not surprisingly) a higher 
s-lactate (p<0.05) after surgery while those receiving Plasmalyte had no significant acid-base changes 
[26]. Consequently, in the retrospective study by Raghunathan et al. in ICU patients with sepsis receiving 
a balanced crystalloid (97.7% received lactated Ringer’s) had a lower 48h mortality, with a relative risk of 
0.86 (95%CI 0.78-0.94 p=0.001) when compared to saline solution. They also performed a dose-response 
analysis and found that mortality was lowered by 3.4% for every 10% increase in proportion of balanced 
crystalloid. No significant difference in acute renal failure was seen [39]. 
 
General articles 
Annane et al. compared all forms of colloid with all forms of crystalloid treatment in ICU patients. In their 
study no significant difference in mortality was seen at 28 days but at 90 days the colloid group had a 
beneficial relative risk of mortality at 0.92 (95%CI 0.86-0.99 p=0.03). Subgroup analysis showed that HES 
gave a survival benefit vs saline solution (RR 0.79 95%CI 0.66-0.95) but not against lactated Ringer’s 
solution. No other colloid showed a significant benefit in this subgroup analysis. When comparing only 
patients with sepsis, none of the studied fluids produced a significantly lower mortality. Need for renal 
replacement therapy was similar in the colloid and crystalloid groups [32]. 
Yunos et al. compared a chloride restrictive (mainly Hartmann´s solution) therapy period vs a chloride 
liberal (mainly saline solution) period in critically ill patients. No significant difference in mortality was 
identified when comparing the two periods. There were less patients with more benign RIFLE-scores I & 
F in the restrictive period, 8.4% vs 14% (p<0.001). Less patients receiving the chloride restrictive therapy 
also required renal replacement therapy, 6.3% vs 10.0% (p=0.005) [31]. 
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Meta-analysis 
Thirteen studies comparing crystalloid with colloid treatment were selected for meta-analysis. Only 
studies that presented the number of deaths and need of renal replacement therapy as endpoints in 
both groups were included. (Figure 1) The main characteristics of included studies are summarized in 
Table 2. One study by Annane et al compared all forms of crystalloid treatment to treatment with all 
forms of colloid solutions, seven studies compared saline to HES, one study by Perner et al. compared 
Ringers acetate to HES and four studies compared saline to albumin. Study settings and definitions of 
clinical outcome were found to differ considerably between the studies. Seven studies included only ICU 
patients, one study included only burn victims, one study included only children with malaria sepsis in a 
non-ICU setting and one study was performed on perioperative patients. Twelve studies compared total 
number of deaths and seven studies compared need of renal replacement therapy in both the crystalloid 
and colloid group. A number of 13 studies were randomized and 9 were blinded. Nine studies scored 
higher than 3 in the Jadad scale. In sepsis patients use of 4% albumin for resuscitation may decrease 
mortality compared to saline solution as found by Finfer et al 2011, but when including large randomized 
studies using 20% albumin in combination with crystalloid as the study by Caironi et al 2014 et al, or 
studies assessing other critically ill patient groups as Finfer et al 2004 and Matiland et al 2011, this 
decrease in mortality cannot be confirmed. Albumin 4 % or albumin 20% in combination with crystalloids 
could be considered safe for critically ill and patients with severe sepsis. (Figure 2) HES may increase 
mortality and risk of renal replacement therapy in critically ill patients, compared to saline and to 
Ringer’s acetate solution [17, 18, 25, 27, 29, 32, 35]. 
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Figure 2 Meta-analysis of studies comparing crystalloid to colloid treatment presenting results from 
endpoints number of deaths and need for renal replacement therapy (RRT) 
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Cross-sectional Survey 
Of 100 recipients 62 fully answered the survey, giving a 62% answering rate. Out of 62 respondents in 
our survey 56% and 69% answered that they used both crystalloid and colloid solutions for perioperative 
and sepsis resuscitation respectively, and 74% that their first hand choice of colloid perioperatively was 
HES. However, when treating septic shock, 89% answered that their preferred colloid was albumin (See 
Figure 3). 
  
Figure 3 Survey answers and comparative distribution. 
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Retrospective data on fluid consumption and expense 
Consumption and cost of blood products from 1998-99 and 2013-14 are presented as well as 
consumption of resuscitation fluid units and their cost from 2013-14. Swedish consumer’s price index for 
the years 1998, 1999, 2013 and 2014 are 257, 258.1, 314 and 313.5 respectively [42]. The number of ICU 
patients at Sahlgrenska University Hospital 2013 and 2014 were 5641 and 5705 respectively [43]. The 
total number of surgical operations (Excluding Queen Silvia’s Children’s Hospital) for the years 1999, 
2013 and 2014 were 46 356, 45 171 and 45 401 respectively.  The price per rbc unit was roughly 800 SEK 
1998-99 and roughly 1000 SEK 2013-14 while the price per plasma unit was roughly 350 SEK 1998-99 and 
roughly 500 SEK 2013-14 (adjusted to price level of 2014). The differences are likely due to revaluations 
after the introduction of leukoreduction. During this time period the consumption of erythrocyte 
concentrate In Sahlgrenska University Hospital increased by approximately 31 % and the indexed cost 
increased markedly by approximately 62 %. However, the consumption of plasma units decreased by 23 
% resulting in a slight increase in cost by 9 % (Figure 4). From the year 2013 to 2014 the spending on 
starch colloid dropped by almost 90 % in the ICU department and by 65 % in the Anesthesia department. 
Correspondingly, the spending on Ringers acetate increased by 19 % and the albumin cost increased by 
37 % in the ICU department. Spending on Ringers acetate in the Anesthesia department remained the 
same while spending on albumin increased by 112%. 
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Figure 4 Units used and cost (index corrected to the price level of 2014) for red blood cell transfusions 
and all types of plasma on Sahlgrenska University Hospital 1998-99 and 2013-14 
1998 1999 2013 2014
Red blood cell units 33 444 28 363 40 880 39 965
Plasma units 11 996 11 121 9332 8373
Red blood cell units cost (SEK) 26 599 028 23 096 858 40 774 090 39 925 035
Plasma units cost (SEK) 4 205 651 3 910 933 4 677 204 4 203 246
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Table 3 Resuscitation fluids used at Sahlgrenska University Hospital 2013-14 
 
 
ICU Units
Crystalloids 2013 2014 Change Change % 2013 2014 Change Change %
Ringer´s acetate 39 976 47 722 7746 19.4 4580 5850 1270 27.7
Rehydrex 45 448 33 489 -11 959 -26.3 4820 3450 -1370 -28.4
Colloids 2013 2014 Change Change % 2013 2014 Change Change %
Albumin 2 731 348 3 744 037 1 012 689 37.1 8903 10 174 1271 14.3
Macrodex 6050 1150 -4900 -81 60 12 -48 -80
Rheomacrodex
Rescueflow 20 832 14 880 -5952 -28.6 42 30 -12 -28.6
Gelofusine 19 040 0 -19 040 -100 340 0 -340 -100
Tetraspan 7700 0 -7700 -100 100 0 -100 -100
Venofundin 54 208 0 -54 208 -100 704 0 -704 -100
Volulyte 7080 7080 x 120 120 x
Cost Units
Operating theaters
Crystalloids 2013 2014 Change Change % 2013 2014 Change Change %
Ringer´s acetate 161 569 162 852 1283 0.8 18 266 19 170 904 4.9
Rehydrex 11 432 9154 -2278 -19.9 1410 1060 -350 -24.8
Colloids 2013 2014 Change Change % 2013 2014 Change Change %
Albumin 374494 792982 418488 111.7 1239 2159 920 74.2
Macrodex 68 860 75 958 7098 10.3 684 780 96 14.0
Rheomacrodex 51 300 60 990 9690 18.9 324 312 -12 -3.7
Rescueflow
Gelofusine 3360 1120 -2240 -66.7 60 20 -40 -66.7
Tetraspan 197 120 26 400 -170 720 -86.6 2560 300 -2260 -88.3
Venofundin 100 100 1540 -98 560 -98.5 1300 20 -1280 -98.5
Volulyte 75 520 75 520 x 1280 1280 x
Cost Units
All of SU Hospital
Crystalloids 2013 2014 Change Change % 2013 2014 Change Change %
Ringer´s acetate 2 065 923 2 328 612 262 689 12.7 234 927 272 481 37 554 16.0
Rehydrex 343 985 390 183 46 198 13.4 35 494 32 470 -3 024 -8.5
Colloids 2013 2014 Change Change % 2013 2014 Change Change %
Albumin 8 361 395 10 185 670 1 824 275 21.8 27 210 30 084 2 874 10.6
Macrodex 297 688 326 286 28 598 9.6 2921 3348 427 14.6
Rheomacrodex 62 560 86 347 23 787 38.0 396 444 48 12.1
Rescueflow 32 736 14 880 -17 856 -54.5 66 30 -36 -54.5
Gelofusine 268 800 159 864 -108 936 -40.5 4800 2679 -2 121 -44.2
Tetraspan 361 900 26 400 -335 500 -92.7 4700 300 -4 400 -93.6
Venofundin 805 651 92 517 -713 134 -88.5 5980 1105 -4 875 -81.5
Volulyte 19 844 113 280 93 436 470.9 200 1920 1 720 860.0
Cost Units
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Discussion 
In this review 20 studies were included, data of resuscitation fluid consumption was collected and the 
anesthesiologists of the department of Anesthesia and Intensive Care at Sahlgrenska University Hospital 
responded to a survey. A summary of the evidence found in the systematic review was performed and is 
presented below as well as a comparison with clinical practices based on the cross-sectional and 
retrospective data. 
 
At the emergency room (or when symptoms present) 
Several of the studies investigating critically ill patients randomized their patients up to 24 hours after 
symptoms had presented [16, 18, 35]. Furthermore, a majority of the studies randomized their patients 
at admission to the ICU, thus allowing for treatment based on the clinician’s judgement before this. 
Perner et al. reported that 42% and Brunkhorst et al. 58% of the patients in their crystalloid groups 
received synthetic colloids before randomization [16, 18]. This has been debated before [44-46] and 
considering the figures above the mortality and ARF/RRT data of these studies cannot rule out HES as a 
resuscitation fluid in the initial phase.  
Considering textbook examples of resuscitation fluid ratio needed, such as a colloid-crystalloid ratio of 
1:3, the colloids are put to shame in the studies included in this review where the ratio varied from no 
difference to 1:1.6. This means that the blinded volume of colloids that was given in relation to 
crystalloids in the included studies was about twice the volume recommended based on classic fluid 
distribution theories. Despite this there are some indications of a more effective fluid resuscitation with 
HES vs crystalloid as both Brunkhorst et al. and Myburgh et al. found it more effective at increasing CVP 
[16, 17]. The small reduction in total fluid administered when using colloids may seem immaterial but 
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there are publications pointing out positive fluid balance as a strong prognostic factor of mortality [47, 
48]. 
Maitland et al. also raises the question about the risks involved with a fluid bolus challenge. Without 
access to an ICU and vasopressor treatment, a fluid bolus carries with it the risk of cardiovascular 
collapse due to dampened sympathetic stimulation. At least this seems true in children, but if the results 
can be extrapolated to adults remains to be seen. 
In the light of the latest research a balanced crystalloid is a solid first line choice when encountering 
patients in the early stages of circulatory failure. Modern studies comparing Ringer’s acetate vs control 
are lacking but it is in many ways similar to Plasmalyte. Hydroxyethyl starch may be a feasible second line 
choice.  
 
In the ICU  
Neither Myburgh et al. nor Finfer et al. found any benefit in choosing a colloid for general fluid 
resuscitation in their huge double blinded trials. The results of Annane et al., which favored colloids, 
have comparative weaknesses in that it was an open-label (non-blinded) study and recruited trough 9 
years. The present evidence favors crystalloids as the choice of resuscitation fluid in critically ill patients. 
Although randomized trials are needed to confirm the results, the study by Yunos et al. strengthen the 
view that balanced solutions surpass normal saline. 
All things considered, a balanced crystalloid remains the first choice resuscitation fluid in the ICU. Lack of 
evidence for using either HES or Albumin and in the case of HES, risk of acute renal failure, makes the 
colloids an inferior choice to be considered in specific patient groups. 
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Patients with severe sepsis 
The studies by Perner et al. and Brunkhorst et al. advocate balanced crystalloids over HES in severe 
sepsis. While Perner et al. compares a balanced HES vs a balanced crystalloid, Brunkhorst et al. makes an 
unblinded comparison of an outdated 10% 200/0.45-0.55 HES solution to lactated Ringer’s. This leaves 
the study by Perner et al. as the main speaker against HES in severe sepsis, still of course backed by 
Myburgh et al mentioned above. The results of Guidet et al. were somewhat positive to HES. Their only 
favorable find was a not very impressive but significant ratio of fluid needed of 1:1.24 favoring HES [30]. 
Additionally, the study by Guidet et al. has been accused of reporting bias as they overestimated the 
treatment efficiency and underestimated the safety risks according to Hartog and Reinhart [49]. In the 
choice of what crystalloid to give to sepsis patients, the study by Raghunathan et al. concludes that 
lactated Ringer’s solution is superior to saline solution [39].  
Considering this, severe sepsis patients seem to be a patient group where albumin has a role in 
treatment. Both Finfer et al. and Caironi et al. found indications that albumin is superior to crystalloids in 
fluid resuscitation of severe sepsis patients, although both are cautious in the interpretation of their 
results [27, 35]. Adding to the doubt, Caironi et al. had several protocol violations only mentioned in the 
supplementary appendix. Roughly 23% of the patients in both groups received a synthetic colloid at least 
once. Furthermore, since Finfer et al. compared albumin to saline, how well does it stand against a 
balanced crystalloid? 
In conclusion, when choosing resuscitation fluid in severe sepsis, both albumin and balanced crystalloids 
seems to be valid alternatives but they need to be compared in future studies. 
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Non-sepsis ICU patients 
In burn victims, the Study of Bechir et al. found similar outcomes using a combination of HES and 
lactated Ringer’s compared to lactated Ringer’s only. Although not a revolutionary find, it raises the 
question why EMA-PRAC advises against HES in burn victims.  
James et al. found HES superior in patients with penetrating trauma and explains the lack of such 
findings in blunt trauma with large difference in damage severity in those groups. 
Again, a balanced crystalloid is an adequate first choice but HES might very well still have a future in 
trauma fluid resuscitation. Albumin on the other hand should be considered contraindicated in trauma 
with suspected brain injury according to the predefined subgroup analysis in Finfer et al.’s study [25]. 
 
In the surgical theatre 
Although there were fewer patients in the included studies examining perioperative fluid resuscitation 
HES solutions seems promising in both fluid resuscitation and as spinal anesthesia preload. There is not 
much evidence that should raise concern for increased risk of renal injury, though studies with long term 
follow up are necessary. Hadimioglu et al. found that Plasmalyte may have benefits over lactated 
Ringer’s but of its superior to Ringer’s acetate remain to be seen in future randomized trials.  
Considering current knowledge, a combination of balanced crystalloids and HES can be regarded as a 
valid choice in perioperative fluid resuscitation. 
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Adaption to current research in the Department of Anesthesiology and Intensive Care 
In the surgical theatre 
Regarding fluid resuscitation in the surgical theatre, the responders´ answers were mainly consistent 
with the findings in our reviewed articles. All responders used balanced crystalloids as opposed to saline 
solution which hardly comes as a surprise in Sweden, but is unusual from an international point of view. 
Choice of colloid had wider diversity. HES solutions were the most common choice followed by Dextrans, 
Albumin and Gelatins (46, 6, 5 and 4 answers of 62 respectively). Since Macrodex is a Swedish invention 
a stronger tradition in our department is to be expected but it is sparsely used internationally. 
Comparing the answers with fluid consumption 2014, reported gelatin use can be considered negligible. 
However, reported albumin use stands out as 8% of the responders answered that they prefer albumin 
as their first choice in perioperative fluid resuscitation. Currently Finfer et al.´s SAFE study backed by 
Caironi et al.´s ALBIOS study are the only evidence for albumin use and do not cover perioperative use. 
Spending on Albumin in perioperative use increased by 111.7% between 2013 and 2014 alone, with a 
total cost more than 10 times that of Volulyte (Table 3).   
 
Patients with severe sepsis 
The second part of the survey covered treatment of septic shock. Again the responders were on par with 
contemporary research. Excluding the resident anesthesiologists who had yet to have their ICU training, 
all responders chose Ringer’s acetate and/or albumin as resuscitation fluids in septic shock. It seems as 
pharmaceutical companies are well aware of the change in practice as the ICU unit price of albumin went 
from 309.6 SEK to 364.9 SEK between 2013 and 2014 and that of Volulyte from 99.2 SEK to 59 SEK. In 
2014 the Sahlgrenska University Hospital ICUs spent roughly three point seven million SEK on albumin, 
97.5% of the total resuscitation fluid spending of 2014 (of the fluids presented in this material). 
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Considering that the main evidence for albumin use in sepsis (the SAFE study by Finfer et al.) compares 
with 0.9% Sodium Chloride, studies comparing albumin to balanced crystalloids are sorely needed. 
Further, cost-effectiveness analyses are necessary. 
 
Retrospective data on blood-product consumption and expense 
Regarding transfusions in Sahlgrenska University Hospital (SU), red blood cell transfusions have increased 
about 30% during the last 15 years, although the number of surgical procedures is roughly the same. 
There are many possible explanations for this, especially since the numbers reflect the whole of 
Sahlgrenska University Hospital. During this time period a large reorganization of the public health 
service has led to an increased concentration of high-risk surgery to the SU. Further studies would be 
necessary to establish any connection to HES which was associated with increased transfusion need in 
several of the articles reviewed [16-18, 28]. In the same time period plasma transfusions went down by 
roughly 23%, which probably is a result of a conscious introduction of a more restrictive policy regarding 
plasma transfusions in the perioperative and intensive care units in SU. 
 
Conclusions and Implications 
Balanced crystalloids have an important role in fluid resuscitation but further research comparing 
balanced crystalloids is needed. Albumin is the preferred colloid in severe sepsis but declaring it 
contraindicated as resuscitation fluid in brain injury ought to be considered. In other scenarios than 
sepsis HES may be considered.  
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The anesthesiologists at the Department of Anesthesiology and Intensive Care had a good adherence to 
current research although perioperative albumin use ought to be reconsidered due to high cost and lack 
of evidence. 
 
Populärvetenskaplig sammanfattning (svenska) 
Vätsketerapi – en litteraturöversikt och enkätundersökning 
Sedan 1800-talets kolera epidemi i England har vätskeersättningsdropp med koksaltlösning varit en del 
av vården som erbjuds svårt sjuka med lågt blodtryck. Idag används många sorters vätskor för detta. 
Några vanliga exempel förutom koksaltlösning är balanserad saltlösning (med en mer naturlig saltbalans 
än koksaltlösning), donerat mänskligt albumin samt stärkelselösningar (HES). 
1998 släpptes en omfattande forskningsrapport som visade att albumin som behandling mot lågt 
blodtryck ledde till ökad dödlighet. Därefter slutade man nästan helt att använda albumin i detta syfte. 
HES blev istället populärt vid behandling av lågt blodtryck.  På senare år har pendeln svängt tillbaka igen 
efter forskningsrapporter som förespråkar albumin och andra som belyser riskerna med HES. 
Med denna artikel har vi gjort en litteraturöversikt av det nuvarande forskningsläget angående 
vätskedropp till svårt sjuka samt även gjort en enkätanalys och granskat statistiska data för att ta reda på  
hur detta efterföljs på AnOpIVA-kliniken på Sahlgrenska Universitetssjukhuset. 
I vår litteraturöversikt har vi tittat på stora studier gjorda under de senaste 15 åren. De visar att Albumin 
bör användas vid behandling av svår blodförgiftning (sepsis) men att det bör undvikas hos patienter med 
misstänkt hjärnskada. HES däremot bör undvikas vid sepsisbehandling då det i detta sammanhang kan 
orsaka njurskada och ökat behovet av dialys. Möjligen kan det även leda till ökad dödlighet. I övriga 
sammanhang där lågt blodtryck behöver behandlas med vätska rekommenderas dock balanserade 
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saltlösningar. HES kan vara ett bra komplement till behandlingen av lågt blodtryck pga. blödning men fler 
studier behövs för att säkerställa detta.  
Vår enkät där 62% svarade visar att en klar majoritet av läkarna på AnOpIVA-kliniken verkar hålla med 
om vår tolkning av den senaste forskningen. Dock ser vi både i enkäten och i vårt statistikunderlag att allt 
mer albumin används under operationer vilket det inte finns något stöd för i forskningen. Under 
operationer bör HES kunna ta en större roll vilket skulle kunna leda till att 100 000-tals kronor årligen i 
besparingar. 
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Appendices 
Appendix 1: 
 
 
 
1 4 When treating septic shock I use:
* Only crystalloid fluid infusion
* Only colloid fluid infusion
* Only crystalloid fluid infusion * Both crystalloid and colloid fluid infusion
* Only colloid fluid infusion * Cannot answer/Other
* Both crystalloid and colloid fluid infusion * Comments
* Cannot answer/Other
* Comments
2 5
* Ringer´s Acetate
* Ringer´s Acetate * Sodium Chloride 9 mg/ml
* Sodium Chloride 9 mg/ml * Cannot answer/Other
* Cannot answer/Other * Comments
* Comments
3 6
*
*
*
*
* Gelatin based colloid (ie Gelofusin)
* Gelatin based colloid (ie Gelofusin) * Albumin
* Albumin * Plasma
* Plasma * Cannot answer/Other
* Cannot answer/Other * Comments
* Comments
Starch based colloid (ie Venofundin, 
Volulyte, Tetraspan)
My first choice of crystalloid fluid when 
treating septic shock is:
My first choice of colloid fluid when 
treating septic shock is:
Dextran based colloid (ie Macrodex, 
Plasmodex)
Starch based colloid (ie Venofundin, 
Volulyte, Tetraspan)
Survey sent to An/Op/IVA anaesthesiologists
When treating a not yet transfusion 
demanding perioperative bleeding I use 
(ASA 1 patient):
My first choice of crystalloid fluid when 
treating a not yet transfusion demanding 
perioperative bleeding is (ASA 1 patient):
My first choice of colloid when treating a 
not yet transfusion demanding 
perioperative bleeding is (ASA 1 patient):
Dextran based colloid (ie Macrodex, 
Plasmodex)
